FAS-dependent endogenous fatty acid metabolism may represent a valuable molecular avenue for developing FAS-based chemopreventive and/or chemotherapeutic strategies in Her-2/neu-related breast cancer.

Targeting Fatty Acid Synthase: Potential for Therapeutic Intervention in Her-2/neu- Overexpressing Breast Cancer

by Javier A. Menendez, Ruth Lupu and Ramon Colomer

Summary

Fatty acid synthase (FAS)-catalyzed de novo fatty acid biosynthesis, an anabolic energy-storage pathway largely considered of minor importance in humans, actively contributes to the cancer phenotype by virtue of its ability to specifically regulate the expression and activity of Her-2/neu (erbB-2) oncogene. First, a positive correlation between high levels of FAS expression and/or activity and the amplification and/or overexpression of Her-2/neu oncogene exists in human breast cancer cell lines. Second, Her-2/neu overexpression stimulates the activity of FAS gene promoter and ultimately mediates increased endogenous fatty acid biosynthesis, while this Her-2/neu-induced upregulation of breast cancer-associated FAS is inhibitable by anti-Her-2/neu antibodies such as trastuzumab (Herceptin™). Third, pharmacological inhibition of FAS activity negatively regulates the expression and tyrosine-kinase activity of Her-2/neu-coded p185^Her-2/neu oncoprotein. ©2005 Prous Science. All rights reserved.